288 related articles for article (PubMed ID: 28002433)
21. Structure-Based Immunogenicity Prediction of Uricase from Fungal (Aspergillus flavus), Bacterial (Bacillus subtillis) and Mammalian Sources Using Immunoinformatic Approach.
Tripathi S; Parmar J; Kumar A
Protein J; 2020 Apr; 39(2):133-144. PubMed ID: 32221804
[TBL] [Abstract][Full Text] [Related]
22. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
Lipsky PE; Calabrese LH; Kavanaugh A; Sundy JS; Wright D; Wolfson M; Becker MA
Arthritis Res Ther; 2014 Mar; 16(2):R60. PubMed ID: 24588936
[TBL] [Abstract][Full Text] [Related]
23. Molecular Elucidation of a Urate Oxidase from
Chiu YC; Hsu TS; Huang CY; Hsu CH
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070642
[TBL] [Abstract][Full Text] [Related]
24. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
[TBL] [Abstract][Full Text] [Related]
25. Pegloticase and the patient with treatment-failure gout.
Dave AJ; Kelly VM; Krishnan E
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
[TBL] [Abstract][Full Text] [Related]
26. Pegloticase: in treatment-refractory chronic gout.
Lyseng-Williamson KA
Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
[TBL] [Abstract][Full Text] [Related]
27. Update on emerging urate-lowering therapies.
Chohan S; Becker MA
Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
[TBL] [Abstract][Full Text] [Related]
28. Enzyme-entrapped mesoporous silica for treatment of uric acid disorders.
Muthukoori S; Narayanan N; Chandra MS; Sethuraman S; Krishnan UM
J Biomed Nanotechnol; 2013 May; 9(5):907-14. PubMed ID: 23802423
[TBL] [Abstract][Full Text] [Related]
29. Biochemical and biopharmaceutical properties of PEGylated uricase.
Freitas Dda S; Spencer PJ; Vassão RC; Abrahão-Neto J
Int J Pharm; 2010 Mar; 387(1-2):215-22. PubMed ID: 19969053
[TBL] [Abstract][Full Text] [Related]
30. Pegloticase (krystexxa) for treatment of refractory gout.
Med Lett Drugs Ther; 2011 Feb; 53(1357):9-10. PubMed ID: 21304442
[No Abstract] [Full Text] [Related]
31. Refractory gout: what is it and what to do about it?
Fels E; Sundy JS
Curr Opin Rheumatol; 2008 Mar; 20(2):198-202. PubMed ID: 18349751
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
[TBL] [Abstract][Full Text] [Related]
33. A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase.
Freyne B
Transplant Proc; 2018 Dec; 50(10):4099-4101. PubMed ID: 30577324
[TBL] [Abstract][Full Text] [Related]
34. Modification with polysialic acid-PEG copolymer as a new method for improving the therapeutic efficacy of proteins.
Wu J; Lu S; Zheng Z; Zhu L; Zhan X
Prep Biochem Biotechnol; 2016 Nov; 46(8):788-797. PubMed ID: 26829568
[TBL] [Abstract][Full Text] [Related]
35. Self-Cascade Uricase/Catalase Mimics Alleviate Acute Gout.
Lin A; Sun Z; Xu X; Zhao S; Li J; Sun H; Wang Q; Jiang Q; Wei H; Shi D
Nano Lett; 2022 Jan; 22(1):508-516. PubMed ID: 34968071
[TBL] [Abstract][Full Text] [Related]
36. Species and sex differences in the blood clearance and immunogenicity of PEGylated uricase: A comparative 26-week toxicity study in rats and monkeys.
Zhang C; Fan K; Luo H; Cheng Y; Lu Y; Zheng J; Chen Z; Xue J; Zhao Q; Zhang M; Ge Y; Hu C; Bai Y; Yang L; Ma X; Chen M; Zhao Z; Shi X
Life Sci; 2020 Aug; 255():116892. PubMed ID: 31610209
[TBL] [Abstract][Full Text] [Related]
37. Use of the uricase-inhibited rat as an animal model in toxicology.
Stavric B; Nera EA
Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
[TBL] [Abstract][Full Text] [Related]
38. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
Hershfield MS; Ganson NJ; Kelly SJ; Scarlett EL; Jaggers DA; Sundy JS
Arthritis Res Ther; 2014 Mar; 16(2):R63. PubMed ID: 24602182
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and antigenicity of soluble cross-linked enzyme/albumin polymers: Advantages for enzyme therapy.
Remy MH; Poznansky MJ
Lancet; 1978 Jul; 2(8080):68-70. PubMed ID: 78296
[TBL] [Abstract][Full Text] [Related]
40. Soluble expression of bioactive recombinant porcine-human chimeric uricase mutant employing MBP-SUMO fusion system.
Zhou Z; Zhao H; Zhang L; Xie Q; Liu Q; Tong M; Yu X; Xiong S
Protein Expr Purif; 2022 Jan; 189():105978. PubMed ID: 34562586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
